Bristol, J&J, Bayer, and other big pharmas are developing new treatments to prevent blood clots to lessen the possibility of unintentional bleeding. According to estimates, blood clots account for around 1 in 4 fatalities globally, and the most popular medications for treating them are the main blood thinners. The medications are referred to as Factor Xa inhibitors for the enzyme they block in the body's normal clotting process and are sold under the trade names Eliquis and Xarelto.